We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

17 hedge funds and large institutions have $787K invested in Titan Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

4% more capital invested

Capital invested by funds: $759K → $787K (+$28.5K)

0.01% less ownership

Funds ownership: 0.33% → 0.32% (-0.01%)

15% less funds holding

Funds holding: 20 → 17 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
1
Closed
3
Calls
$9K
Puts
–
Net Calls
+$9K
Net Calls Change
-$12K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.22K
2
Renaissance Technologies
Renaissance Technologies
New York
+$895
3
Group One Trading
Group One Trading
Illinois
+$36

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$16K
2
IA
IFP Advisors
Florida
-$1K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$233
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$156
Name Holding Trade Value Shares
Change 		Change in
Stake
Truist Financial
1
Truist Financial
North Carolina
$519K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$112K +$895 +50 +0.7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$68.1K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$53K – – –
State Street
5
State Street
Massachusetts
$31.7K – – –
UBS Group
6
UBS Group
Switzerland
$1.27K +$1.22K +68 +850%
TRCT
7
Tower Research Capital (TRC)
New York
$1K – – –
LFA
8
Level Financial Advisors
New York
$819 – – –
Group One Trading
9
Group One Trading
Illinois
$273 +$36 +2 +13%
Bank of America
10
Bank of America
North Carolina
$170 – – –
Wells Fargo
11
Wells Fargo
California
$65 – – –
Fidelity Investments
12
Fidelity Investments
Massachusetts
$58 -$233 -13 -76%
BlackRock
13
BlackRock
New York
$50 – – –
GWSA
14
Global Wealth Strategies & Associates
Colorado
$33 – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$29 – – –
Morgan Stanley
16
Morgan Stanley
New York
$23 – – –
WIM
17
Westside Investment Management
California
$3 – – –
CSC
18
Caldwell Sutter Capital
California
$2 – – –
NFSG
19
Newbridge Financial Services Group
Florida
$2 – – –
CIA
20
Cape Investment Advisory
Georgia
$1 – – –
VF
21
Virtu Financial
New York
– -$16K -1,004 Closed
PNC Financial Services Group
22
PNC Financial Services Group
Pennsylvania
– -$156 -10 Closed
IA
23
IFP Advisors
Florida
– -$1K -1 Closed

TTNP Hedge Fund Activity: Q1 2023 in Review

17 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2023, worth a combined $787K — up 3.8% from $759K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TTNP and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was UBS Group, adding an estimated $1.22K. The largest seller was Virtu Financial, exiting entirely with an estimated $16K sold.

  • 17 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2023, down from 20 in Q4 2022.
  • Funds reported $787K of Titan Pharmaceuticals stock for Q1 2023, up 3.8% quarter-over-quarter.
  • 0 funds opened new Titan Pharmaceuticals positions in Q1 2023 and 3 closed out, a net change of -3 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2023 was UBS Group, an estimated $1.22K added.
  • The largest Titan Pharmaceuticals seller in Q1 2023 was Virtu Financial, an estimated $16K sold.

Based on aggregated 13F filings for Q1 2023.